NCT03839940: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

NCT03839940
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Other, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be about to receive oral everolimus 10 mg/day with or without an endocrine agent; Patients about to receive everolimus for off label use are also eligible
Exclusions: 
https://ClinicalTrials.gov/show/NCT03839940

Comments are closed.

Up ↑